U24NS129500

Yale-Metro Metropolitan Emergency Trial Network to Advance Patient Outcomes - The Yale-Metro Trial Network to Advance Patient Outcomes (Yale-Metro) is anchored by Yale New Haven Health System (YNHHS) as the hub and 5 leading partner integrated health systems. (1) Hartford Healthcare, (2) Rhode Island/Brown University Health System, (3) Mount Sinai Health System, (4) New York Presbyterian/Weill Cornell Medicine, and (5) Montefiore Health System. Yale-New Haven Hospital is the 7th largest hospital in the U.S. and, in collaboration with YNHHS and the spokes with their respective networks, these geographically proximate institutions cover a densely populated catchment area including more than 8 million people throughout Connecticut, Rhode Island, Southeast NY, Southern MA, and 4 boroughs of New York City, with 1,739,027 emergency department visits. Offering access to a large and diverse population of acutely ill adult and pediatric patients.

Principal investigators Dr. Gail D'Onofrio (Emergency Medicine) and Dr. Kevin Sheth (Neurology) bring a complementary set of leadership skills, high-level clinical trial experience, and an excellent organizational framework. Each have demonstrated expertise in leading and conducting multicenter trials and a proven track record of high-quality ED and pre-hospital recruitment and retention in studies, even during the COVID-19 pandemic. They have collaborated and are actively engaged in multicenter trials with the spoke institutions and investigators. These interactions include leveraging successful contributions currently in place for NIH networks such as NeuroNEXT and StrokeNet. They have access to a cadre of impressive multispecialty faculty, creating a highly collaborative environment focused on the emergency care related to presentations and diagnoses of interest including neurological, cardiovascular, respiratory, hematology, and trauma. Finally, they have created mechanisms to facilitate enrollment 24 hours, 7 days a week that are already in place.

The proposal is strengthened by a: (1) pool of talented investigators with nationally recognized researchers and MPIs with experience implementing multicenter trials, (2) large diverse patient population, (3) informaticist and analytic team bringing innovative technological strategies and processes for rapid uptake of spokes, recruitment, data collection, monitoring, and quality, (4) robust track record of mentoring junior investigators, and (5) expertise in developing future proposals for SIREN research. Yale-Metro offers all the components for conducting high-quality research and unique opportunities to use innovative technology advances for disease detection, patient enrollment, data collection, and high-quality assurance procedures. Thus, Yale-Metro offers unique opportunities to strengthen the SIREN network, designing, testing, and discovering interventions and therapies improving patient outcomes.

Yale Univ

(1) TO SUPPORT EXTRAMURAL RESEARCH FUNDED BY THE NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE (NINDS) INCLUDING: BASIC RESEARCH THAT EXPLORES THE FUNDAMENTAL STRUCTURE AND FUNCTION OF THE BRAIN AND THE NERVOUS SYSTEM, RESEARCH TO UNDERSTAND THE CAUSES AND ORIGINS OF PATHOLOGICAL CONDITIONS OF THE NERVOUS SYSTEM WITH THE GOAL OF PREVENTING THESE DISORDERS, RESEARCH ON THE NATURAL COURSE OF NEUROLOGICAL DISORDERS, IMPROVED METHODS OF DISEASE PREVENTION, NEW METHODS OF DIAGNOSIS AND TREATMENT, DRUG DEVELOPMENT, DEVELOPMENT OF NEURAL DEVICES, CLINICAL TRIALS, AND RESEARCH TRAINING IN BASIC, TRANSLATIONAL AND CLINICAL NEUROSCIENCE. THE INSTITUTE IS THE LARGEST FUNDER OF BASIC NEUROSCIENCE IN THE US AND SUPPORTS RESEARCH ON TOPICS INCLUDING BUT NOT LIMITED TO: DEVELOPMENT OF THE NERVOUS SYSTEM, INCLUDING NEUROGENESIS AND PROGENITOR CELL BIOLOGY, SIGNAL TRANSDUCTION IN DEVELOPMENT AND PLASTICITY, AND PROGRAMMED CELL DEATH, SYNAPSE FORMATION, FUNCTION, AND PLASTICITY, LEARNING AND MEMORY, CHANNELS, TRANSPORTERS, AND PUMPS, CIRCUIT FORMATION AND MODULATION, BEHAVIORAL AND COGNITIVE NEUROSCIENCE, SENSORIMOTOR LEARNING, INTEGRATION AND EXECUTIVE FUNCTION, NEUROENDOCRINE SYSTEMS, SLEEP AND CIRCADIAN RHYTHMS, AND SENSORY AND MOTOR SYSTEMS. IN ADDITION, THE INSTITUTE SUPPORTS BASIC, TRANSLATIONAL AND CLINICAL STUDIES ON A NUMBER OF DISORDERS OF THE NERVOUS SYSTEM INCLUDING (BUT NOT LIMITED TO): STROKE, TRAUMATIC INJURY TO THE BRAIN, SPINAL CORD AND PERIPHERAL NERVOUS SYSTEM, NEURODEGENERATIVE DISORDERS, MOVEMENT DISORDERS, BRAIN TUMORS, CONVULSIVE DISORDERS, INFECTIOUS DISORDERS OF THE BRAIN AND NERVOUS SYSTEM, IMMUNE DISORDERS OF THE BRAIN AND NERVOUS SYSTEM, INCLUDING MULTIPLE SCLEROSIS, DISORDERS RELATED TO SLEEP, AND PAIN. PROGRAMMATIC AREAS, WHICH ARE PRIMARILY SUPPORTED BY THE DIVISION OF NEUROSCIENCE, ARE ALSO SUPPORTED BY THE DIVISION OF EXTRAMURAL ACTIVITIES, THE DIVISION OF TRANSLATIONAL RESEARCH, THE DIVISION OF CLINICAL RESEARCH, THE OFFICE OF TRAINING AND WORKFORCE DEVELOPMENT, THE OFFICE OF PROGRAMS TO ENHANCE NEUROSCIENCE WORKFORCE DEVELOPMENT, AND THE OFFICE OF INTERNATIONAL ACTIVITIES. (2) TO EXPAND AND IMPROVE THE SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. TO UTILIZE THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM, TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.

93.837 - Cardiovascular Diseases Research

National Institute of Neurological Disorders and Stroke (NNDS) [HHS - NIH]

National Heart Lung and Blood Institute (NHLBI) [HHS - NIH]

Connecticut United States

State-Wide

Network for Emergency Care Clinical Trials: Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network Clinical Center (Hub) (U24 Clinical Trial Not Allowed) (RFA-NS-22-015)

Amendment Since initial award the total obligations have increased 380% from $266,297 to $1,277,028.